Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.61 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RAD51 | Q06609 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.49 |
| ▸ | HTR3B | O95264 | 3/20 | 0.49 |
| ▸ | HTR3A | P46098 | 3/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401133 | 0.82 | PTPN1 (0.54) | PTPN1PTPN2KDM4EALDH1A1HPGD | |
| SCHEMBL2460828 | 0.82 | PTPN1 (0.71) | PTPN1PTPN2KDM4EALDH1A1HPGD | |
| SCHEMBL1079670 | 0.79 | RAD51 (0.58) | PTPN1KDM4EALDH1A1HPGDRAD51 | |
| SCHEMBL1309484 | 0.79 | RAD51 (0.58) | PTPN1KDM4EALDH1A1HPGDRAD51 | |
| SCHEMBL7400768 | 0.79 | HTR3E (0.57) | PTPN1PTPN2KDM4EALDH1A1HPGD | |
| SCHEMBL13082235 | 0.79 | RAD51 (0.51) | PTPN1PTPN2KDM4EALDH1A1HPGD | |
| SCHEMBL23917098 | 0.77 | PTPN1 (0.53) | PTPN1PTPN2KDM4EALDH1A1HPGD | |
| SCHEMBL8570625 | 0.77 | HTR3E (0.55) | PTPN1PTPN2KDM4EALDH1A1HPGD | |
| SCHEMBL31377558 | 0.76 | PTPN1 (0.61) | PTPN1PTPN2KDM4EALDH1A1HPGD | |
| SCHEMBL24734786 | 0.76 | PTPN1 (0.61) | PTPN1PTPN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| EP-0623620-B1 | 5-HT3 Pyrrolopyrazine derivatives | ADIR (FR) | 1998-09-09 | — | — | EP | disclosed |
| US-5599812-A | ANTISEROTONINE AGENTS | ADIR ET COMPAGNIE (FR) | 1997-02-04 | — | — | US | disclosed |
| EP-0623620-A1 | 5-HT3 Pyrrolopyrazine derivatives | ADIR ET COMPAGNIE (FR) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | PTPN1 3434/4885PTPN2 3449/4885KDM4E 3554/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | PTPN1 3434/4885PTPN2 3449/4885KDM4E 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.